Cancer Drug, Kadcyla | search
Click here to view Cancer Drug, Kadcyla news from 60+ newspapers.
Bookmark or Share- KADCYLA® (ado-trastuzumab emtansine) in HER2+ Breast CancerLearn about KADCYLA® (ado-trastuzumab emtansine), a treatment for certain patients with early or metastatic HER2+ breast cancer. See Full Safety and Boxed Warnings for more information.
- T-DM1 Approval Expanded for HER2-Positive Breast CancerAdo-trastuzumab emtansine (Kadcyla), or T-DM1, has been approved by FDA for use as adjuvant therapy in some women with early-stage HER2-positive breast cancer.
- Kadcyla (T-DM1): Side Effects, How it Works, and MoreKadcyla (T-DM1) is a targeted therapy used to treat HER2-positive metastatic breast cancer. Learn more about Kadcyla.
- Trastuzumab emtansine - WikipediaTrastuzumab emtansine, [7][8] sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. [9][10][11][12] Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoe...
- KADCYLA® (ado-trastuzumab emtansine) | A HER2+ Breast Cancer ...KADCYLA, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA. Metastatic Breast Cancer (MBC)
More
